Inozyme Pharma Inc Phase 1/2 Trials of INZ-701 Data Update Call Transcript

Sep 26, 2023

Click here to view more INZY transcripts

Sep 26, 2023 / 12:00PM GMT
Operator

Good morning. And welcome to the Inozyme Pharma interim update call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Stefan Riley, Director of Investor Relations. Please go ahead.

Stefan Riley - Inozyme Pharma, Inc. - Director of IR

Good morning. And thank you for joining us for the review of new interim data from our ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 and ABCC6 deficiencies. Today's remarks will be followed by a question-and-answer session with the management team. Please dial in via telephone to participate.

Before we begin our formal remarks, I would like to point you to our forward-looking statements disclaimer. I would now like to turn the conference over to Doug Treco, Chief Executive Officer and Chairman of the Board of Directors of Inozyme Pharma. Please go ahead.

Doug Treco - Inozyme Pharma, Inc. - CEO & Chairman of the Board of Directors

Thanks, Stefan. And thanks, everyone online, for being with us

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.